If Nrf2 upregulation by other Keap1-Cys151-acting compounds, such as dimethyl fumarate or ursodiol (a gallstone dissolver), activated Nrf2 at the same level as CDDO, more trials could be expected to end in termination for patient safety/adverse event reasons. This evidence concerns the gene NFE2L2 and gallstones.